Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits

Detalhes bibliográficos
Autor(a) principal: Filho, Marco Antonio Ferraz Nogueira [UNESP]
Data de Publicação: 2013
Outros Autores: Padilha, Elias Carvalho [UNESP], de Campos, Michel Leandro [UNESP], de Pontes Machado, Diego Vinicius [UNESP], Davanço, Marcelo Gomes [UNESP], Pestana, Kelly Christina [UNESP], Chin, Chung Man [UNESP], Peccinini, Rosângela Gonçalves [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.2174/18723128112069990013
http://hdl.handle.net/11449/227425
Resumo: The prodrug hydroximethylnitrofurazone (NFOH) presents antichagasic activity with greatly reduced toxicity compared to its drug matrix nitrofurazone (NF). Besides these new characteristics, the prodrug was more active against the parasite T. cruzi amastigotes. These advantages make the prodrug a possible therapeutic alternative for the treatment of both acute and the chronic phase of Chagas disease. However, the knowledge of pharmacokinetic profile is crucial to evaluate the feasibility of a new drug. In this study, our objective was to evaluate the in vivo formation of NF from the NFOH single administration and to evaluate its pharmacokinetic profile and compared it to NF administration. A bioanalytical method to determine the NF and NFOH by LCMS/MS was developed and validated to perform these investigations. Male albino rabbits (n=15) received NF intravenously and orally in doses of 6.35 and 63.5 mg / kg respectively, and NFOH, 80.5 mg / kg orally. The serial blood samples were processed and analyzed by mass spectrometry. The system operated in positive and negative modes for the analites determination, under elution of the mobile phase 50:50 water: methanol. The administration of NFOH allowed the calculation of pharmacokinetic parameters for the prodrug, and the NF obtained from NFOH administration. Using the pharmacokinetic profile obtained from the NF i.v. administration, the oral bioavailability of NF from the administered prodrug was obtained (60.1%) and, as a key parameter in a prodrug administration, should be considered in future studies. The i.v. and oral administrations of NF differ in the constant of elimination (0.04 vs 0.002) and elimination half-life (17.32 min vs 276.09 min) due to the low solubility of the drug that hinders the formation of molecular dispersions in the digestory tract. Still, there was observed no statistical differences were observed between the pharmacokinetic parameters of orally administered NF and NF obtained from NFOH. The calculated area under the curve (AUC 0-∞) showed that the exposure to the parental drug was fairly the same (844.79 vs 566.44) for NF and NF obtained from the prodrug administration. The tendency to higher NF's mean residence time (MRT) as observed in the prodrug administration (956.1 min vs 496.3 min) guarantees longer time for the action of the drug and it allows the expansion of the administration intervals. These findings, added with the beneficial characteristics of the prodrug encourage new efficacy tests towards the clinical use of NFOH. ©2013 Bentham Science Publishers.
id UNSP_2e6afa9ccf31d6a015a62c1ae8684514
oai_identifier_str oai:repositorio.unesp.br:11449/227425
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbitsChagas diseaseHydroxymthylnitrofurazoneNitrofurazonePharmacokineticsMarco Antonio Ferraz Nogueira Filhoa, Elias Carvalho Padilhaa, Michel Leandro de Camposa,The prodrug hydroximethylnitrofurazone (NFOH) presents antichagasic activity with greatly reduced toxicity compared to its drug matrix nitrofurazone (NF). Besides these new characteristics, the prodrug was more active against the parasite T. cruzi amastigotes. These advantages make the prodrug a possible therapeutic alternative for the treatment of both acute and the chronic phase of Chagas disease. However, the knowledge of pharmacokinetic profile is crucial to evaluate the feasibility of a new drug. In this study, our objective was to evaluate the in vivo formation of NF from the NFOH single administration and to evaluate its pharmacokinetic profile and compared it to NF administration. A bioanalytical method to determine the NF and NFOH by LCMS/MS was developed and validated to perform these investigations. Male albino rabbits (n=15) received NF intravenously and orally in doses of 6.35 and 63.5 mg / kg respectively, and NFOH, 80.5 mg / kg orally. The serial blood samples were processed and analyzed by mass spectrometry. The system operated in positive and negative modes for the analites determination, under elution of the mobile phase 50:50 water: methanol. The administration of NFOH allowed the calculation of pharmacokinetic parameters for the prodrug, and the NF obtained from NFOH administration. Using the pharmacokinetic profile obtained from the NF i.v. administration, the oral bioavailability of NF from the administered prodrug was obtained (60.1%) and, as a key parameter in a prodrug administration, should be considered in future studies. The i.v. and oral administrations of NF differ in the constant of elimination (0.04 vs 0.002) and elimination half-life (17.32 min vs 276.09 min) due to the low solubility of the drug that hinders the formation of molecular dispersions in the digestory tract. Still, there was observed no statistical differences were observed between the pharmacokinetic parameters of orally administered NF and NF obtained from NFOH. The calculated area under the curve (AUC 0-∞) showed that the exposure to the parental drug was fairly the same (844.79 vs 566.44) for NF and NF obtained from the prodrug administration. The tendency to higher NF's mean residence time (MRT) as observed in the prodrug administration (956.1 min vs 496.3 min) guarantees longer time for the action of the drug and it allows the expansion of the administration intervals. These findings, added with the beneficial characteristics of the prodrug encourage new efficacy tests towards the clinical use of NFOH. ©2013 Bentham Science Publishers.Departamento de Princípios Ativos Naturais e Toxicologia UNESP, Rodovia Araraquara Jaú Km. 01, 14801-902 Araraquara, SPDepartamento de Princípios Ativos Naturais e Toxicologia UNESP, Rodovia Araraquara Jaú Km. 01, 14801-902 Araraquara, SPUniversidade Estadual Paulista (UNESP)Filho, Marco Antonio Ferraz Nogueira [UNESP]Padilha, Elias Carvalho [UNESP]de Campos, Michel Leandro [UNESP]de Pontes Machado, Diego Vinicius [UNESP]Davanço, Marcelo Gomes [UNESP]Pestana, Kelly Christina [UNESP]Chin, Chung Man [UNESP]Peccinini, Rosângela Gonçalves [UNESP]2022-04-29T07:13:15Z2022-04-29T07:13:15Z2013-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article58-64http://dx.doi.org/10.2174/18723128112069990013Drug Metabolism Letters, v. 7, n. 1, p. 58-64, 2013.1872-3128http://hdl.handle.net/11449/22742510.2174/187231281120699900132-s2.0-84891879595Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengDrug Metabolism Lettersinfo:eu-repo/semantics/openAccess2024-06-24T14:51:23Zoai:repositorio.unesp.br:11449/227425Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T14:05:38.689877Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits
title Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits
spellingShingle Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits
Filho, Marco Antonio Ferraz Nogueira [UNESP]
Chagas disease
Hydroxymthylnitrofurazone
Nitrofurazone
PharmacokineticsMarco Antonio Ferraz Nogueira Filhoa, Elias Carvalho Padilhaa, Michel Leandro de Camposa,
title_short Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits
title_full Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits
title_fullStr Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits
title_full_unstemmed Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits
title_sort Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits
author Filho, Marco Antonio Ferraz Nogueira [UNESP]
author_facet Filho, Marco Antonio Ferraz Nogueira [UNESP]
Padilha, Elias Carvalho [UNESP]
de Campos, Michel Leandro [UNESP]
de Pontes Machado, Diego Vinicius [UNESP]
Davanço, Marcelo Gomes [UNESP]
Pestana, Kelly Christina [UNESP]
Chin, Chung Man [UNESP]
Peccinini, Rosângela Gonçalves [UNESP]
author_role author
author2 Padilha, Elias Carvalho [UNESP]
de Campos, Michel Leandro [UNESP]
de Pontes Machado, Diego Vinicius [UNESP]
Davanço, Marcelo Gomes [UNESP]
Pestana, Kelly Christina [UNESP]
Chin, Chung Man [UNESP]
Peccinini, Rosângela Gonçalves [UNESP]
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (UNESP)
dc.contributor.author.fl_str_mv Filho, Marco Antonio Ferraz Nogueira [UNESP]
Padilha, Elias Carvalho [UNESP]
de Campos, Michel Leandro [UNESP]
de Pontes Machado, Diego Vinicius [UNESP]
Davanço, Marcelo Gomes [UNESP]
Pestana, Kelly Christina [UNESP]
Chin, Chung Man [UNESP]
Peccinini, Rosângela Gonçalves [UNESP]
dc.subject.por.fl_str_mv Chagas disease
Hydroxymthylnitrofurazone
Nitrofurazone
PharmacokineticsMarco Antonio Ferraz Nogueira Filhoa, Elias Carvalho Padilhaa, Michel Leandro de Camposa,
topic Chagas disease
Hydroxymthylnitrofurazone
Nitrofurazone
PharmacokineticsMarco Antonio Ferraz Nogueira Filhoa, Elias Carvalho Padilhaa, Michel Leandro de Camposa,
description The prodrug hydroximethylnitrofurazone (NFOH) presents antichagasic activity with greatly reduced toxicity compared to its drug matrix nitrofurazone (NF). Besides these new characteristics, the prodrug was more active against the parasite T. cruzi amastigotes. These advantages make the prodrug a possible therapeutic alternative for the treatment of both acute and the chronic phase of Chagas disease. However, the knowledge of pharmacokinetic profile is crucial to evaluate the feasibility of a new drug. In this study, our objective was to evaluate the in vivo formation of NF from the NFOH single administration and to evaluate its pharmacokinetic profile and compared it to NF administration. A bioanalytical method to determine the NF and NFOH by LCMS/MS was developed and validated to perform these investigations. Male albino rabbits (n=15) received NF intravenously and orally in doses of 6.35 and 63.5 mg / kg respectively, and NFOH, 80.5 mg / kg orally. The serial blood samples were processed and analyzed by mass spectrometry. The system operated in positive and negative modes for the analites determination, under elution of the mobile phase 50:50 water: methanol. The administration of NFOH allowed the calculation of pharmacokinetic parameters for the prodrug, and the NF obtained from NFOH administration. Using the pharmacokinetic profile obtained from the NF i.v. administration, the oral bioavailability of NF from the administered prodrug was obtained (60.1%) and, as a key parameter in a prodrug administration, should be considered in future studies. The i.v. and oral administrations of NF differ in the constant of elimination (0.04 vs 0.002) and elimination half-life (17.32 min vs 276.09 min) due to the low solubility of the drug that hinders the formation of molecular dispersions in the digestory tract. Still, there was observed no statistical differences were observed between the pharmacokinetic parameters of orally administered NF and NF obtained from NFOH. The calculated area under the curve (AUC 0-∞) showed that the exposure to the parental drug was fairly the same (844.79 vs 566.44) for NF and NF obtained from the prodrug administration. The tendency to higher NF's mean residence time (MRT) as observed in the prodrug administration (956.1 min vs 496.3 min) guarantees longer time for the action of the drug and it allows the expansion of the administration intervals. These findings, added with the beneficial characteristics of the prodrug encourage new efficacy tests towards the clinical use of NFOH. ©2013 Bentham Science Publishers.
publishDate 2013
dc.date.none.fl_str_mv 2013-01-01
2022-04-29T07:13:15Z
2022-04-29T07:13:15Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.2174/18723128112069990013
Drug Metabolism Letters, v. 7, n. 1, p. 58-64, 2013.
1872-3128
http://hdl.handle.net/11449/227425
10.2174/18723128112069990013
2-s2.0-84891879595
url http://dx.doi.org/10.2174/18723128112069990013
http://hdl.handle.net/11449/227425
identifier_str_mv Drug Metabolism Letters, v. 7, n. 1, p. 58-64, 2013.
1872-3128
10.2174/18723128112069990013
2-s2.0-84891879595
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Drug Metabolism Letters
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 58-64
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128314371473408